Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21155831rdf:typepubmed:Citationlld:pubmed
pubmed-article:21155831lifeskim:mentionsumls-concept:C0039421lld:lifeskim
pubmed-article:21155831lifeskim:mentionsumls-concept:C0005821lld:lifeskim
pubmed-article:21155831lifeskim:mentionsumls-concept:C0027950lld:lifeskim
pubmed-article:21155831lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:21155831lifeskim:mentionsumls-concept:C0301630lld:lifeskim
pubmed-article:21155831lifeskim:mentionsumls-concept:C0037633lld:lifeskim
pubmed-article:21155831lifeskim:mentionsumls-concept:C0450129lld:lifeskim
pubmed-article:21155831lifeskim:mentionsumls-concept:C0332293lld:lifeskim
pubmed-article:21155831lifeskim:mentionsumls-concept:C0079411lld:lifeskim
pubmed-article:21155831lifeskim:mentionsumls-concept:C0450254lld:lifeskim
pubmed-article:21155831lifeskim:mentionsumls-concept:C0442796lld:lifeskim
pubmed-article:21155831pubmed:issue6lld:pubmed
pubmed-article:21155831pubmed:dateCreated2011-6-10lld:pubmed
pubmed-article:21155831pubmed:abstractTextStorage of cell-containing blood components such as platelet concentrates (PCs) and red blood cells (RBCs) results in generation of biologically active compounds, many of which may be associated with adverse transfusion events. Priming of the neutrophil oxidase activity is a common characteristic of many of the biologically active compounds found in stored blood. We evaluated the priming activity of pathogen reduction technology (PRT)-treated PCs stored in plasma or platelet additive solution (PAS) and PRT-treated RBCs.lld:pubmed
pubmed-article:21155831pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21155831pubmed:languageenglld:pubmed
pubmed-article:21155831pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21155831pubmed:citationSubsetIMlld:pubmed
pubmed-article:21155831pubmed:statusMEDLINElld:pubmed
pubmed-article:21155831pubmed:monthJunlld:pubmed
pubmed-article:21155831pubmed:issn1537-2995lld:pubmed
pubmed-article:21155831pubmed:authorpubmed-author:ThurmanGailGlld:pubmed
pubmed-article:21155831pubmed:authorpubmed-author:AmbrusoDaniel...lld:pubmed
pubmed-article:21155831pubmed:authorpubmed-author:MarschnerSusa...lld:pubmed
pubmed-article:21155831pubmed:authorpubmed-author:TranKhoaKlld:pubmed
pubmed-article:21155831pubmed:authorpubmed-author:GoodrichRaymo...lld:pubmed
pubmed-article:21155831pubmed:authorpubmed-author:JanetzkoKarin...lld:pubmed
pubmed-article:21155831pubmed:authorpubmed-author:GathofBirgitBlld:pubmed
pubmed-article:21155831pubmed:copyrightInfo© 2010 American Association of Blood Banks.lld:pubmed
pubmed-article:21155831pubmed:issnTypeElectroniclld:pubmed
pubmed-article:21155831pubmed:volume51lld:pubmed
pubmed-article:21155831pubmed:ownerNLMlld:pubmed
pubmed-article:21155831pubmed:authorsCompleteYlld:pubmed
pubmed-article:21155831pubmed:pagination1220-7lld:pubmed
pubmed-article:21155831pubmed:meshHeadingpubmed-meshheading:21155831...lld:pubmed
pubmed-article:21155831pubmed:meshHeadingpubmed-meshheading:21155831...lld:pubmed
pubmed-article:21155831pubmed:meshHeadingpubmed-meshheading:21155831...lld:pubmed
pubmed-article:21155831pubmed:meshHeadingpubmed-meshheading:21155831...lld:pubmed
pubmed-article:21155831pubmed:year2011lld:pubmed
pubmed-article:21155831pubmed:articleTitleGeneration of neutrophil priming activity by cell-containing blood components treated with pathogen reduction technology and stored in platelet additive solutions.lld:pubmed
pubmed-article:21155831pubmed:affiliationBonfils Blood Center and the Center for Cancer and Blood Disorders, The Children's Hospital, Denver, Colorado, USA.lld:pubmed
pubmed-article:21155831pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:21155831pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed